Meliodays Medical announces the closing of a pre-seed financing round of over EUR 800,000

Meliodays Medical announces the closing of a pre-seed financing round of over EUR 800,000
 

• Addressing a high unmet medical need in menstrual pain with microdoses of painkillers through local application

Munich, March 20, 2025 – Meliodays Medical GmbH, a young pharmaceutical company focusing on the development of a new therapy for hormone-free, local treatment of menstrual pain, today announces the successful completion of an oversubscribed pre-seed financing round of over EUR 800,000 led by capacura GmbH with participation from FS Life Science Investment GmbH and other early-stage investors and business angels specializing in the healthcare market.

Simone Sabbione, co-founder and CEO of Meliodays Medical, explained: ‘We are delighted to have attracted such experienced healthcare and impact investors for our first financing round and warmly welcome them to the Meliodays shareholder group. Their investment and the strong interest in our significantly oversubscribed pre-seed round show that period pain is now recognized as a significant health burden affecting large portions of the global population. Now, we can finally work on urgently needed innovative solutions.’

About 80 percent of menstruating people experience period pain, with 20-30 percent finding it severe enough to limit their ability to attend school, work and social activities at times, often requiring the use of pain medication. However, currently available treatment options, such as hormone therapies or high-dose painkillers, are often associated with systemic side effects.

Meliodays Medical will use the proceeds to advance the development of MelioOne, a novel, hormone-free, locally acting treatment for menstrual pain, and to complete preparations for the preclinical development of its innovative intrauterine application. Using a proven polymer technology, a very small amount of pain medication is released directly into the uterus, to effectively treat period pain while avoiding systemic side effects. In the future, Meliodays Medical’s innovative technology could also be used in the treatment of endometriosis The company has already secured patent rights for MelioOne in over 150 countries.

About Meliodays Medical

Meliodays Medical GmbH, is a young pharmaceutical company focused on developing a new therapy for hormone-free, local treatment of menstrual pain. Meliodays Medical is developing MelioOne, the first hormone-free, local solution to treat menstrual pain without systemic side effects, thus addressing an area of high unmet medical need. With its innovative healthcare solutions, Meliodays is paving the way to a better quality of life for menstruating people, enabling them to have a pain-free period without affecting their menstrual cycle. For further information, please visit www.meliodays.com and follow us on LinkedIn or Instagram.